Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Addition Of Lunesta To Lexapro Provides Benefits, Study Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The sleep aid combined with Lexapro shows a significant improvement in sleep measures compared to Lexapro and placebo.

You may also be interested in...



Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year

Firm says formulary placement of the sleep aid will help mitigate Rx erosion following the launch of generic Ambien.

Lunesta’s Expanded Sales Force Will Focus On Maintenance Use

Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel